The kinetics and predictors of anti-SARS-CoV-2 antibodies up to 8 months after symptomatic COVID-19: A Czech cross-sectional study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F22%3A10157256" target="_blank" >RIV/00098892:_____/22:10157256 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/22:10444793 RIV/61989592:15110/22:73613731

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/10.1002/jmv.27784" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1002/jmv.27784</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/jmv.27784" target="_blank" >10.1002/jmv.27784</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The kinetics and predictors of anti-SARS-CoV-2 antibodies up to 8 months after symptomatic COVID-19: A Czech cross-sectional study

Popis výsledku v původním jazyce

The presence of neutralizing SARS-CoV-2-specific antibodies indicates protection against (re)infection, however, the knowledge of their long-term kinetics is limited. This study analyzed the presence of COVID-19-induced antibodies in unvaccinated healthcare workers (HCWs) over the period of 1-8 months post symptom onset (SO) and explored the determinants of persisting immunoglobulin (Ig) seropositivity. Six hundred sixty-two HCWs were interviewed for anamnestic data and tested for IgG targeting the spike protein (S1 and S2) and IgM targeting the receptor-binding domain. A Cox regression model was used to explore potential predictors of seropositivity with respect to the time lapse between SO and serology testing. 82.9% and 44.7% of HCWs demonstrated IgG and IgM seropositivity, respectively, with a mean interval of 83 days between SARS-CoV-2 detection and serology testing. On average, HCWs reported seven symptoms in the acute phase lasting 20 days. IgG seropositivity rates among HCWs decreased gradually to 80%, 50%, and 35% at 3, 6, and 8 months after SO, while IgM seropositivity fell rapidly to 60%,15%, and 0% over the same time intervals. The number of symptoms was the only predictor of persisting IgG seropositivity (odds ratio [OR] 1.096, 95% confidence interval [CI] 1.003-1.199, p = 0.043) and symptom duration a predictor of IgM seropositivity (OR 1.011, 95% CI 1.004-1.017, p = 0.002). Infection-induced anti-SARS-CoV-2 IgG rates drop to a third in seropositive participants over the course of 8 months. Symptom count and duration in the acute phase of COVID-19 are both relevant to the subsequent kinetics of antibody responses.

Název v anglickém jazyce

The kinetics and predictors of anti-SARS-CoV-2 antibodies up to 8 months after symptomatic COVID-19: A Czech cross-sectional study

Popis výsledku anglicky

The presence of neutralizing SARS-CoV-2-specific antibodies indicates protection against (re)infection, however, the knowledge of their long-term kinetics is limited. This study analyzed the presence of COVID-19-induced antibodies in unvaccinated healthcare workers (HCWs) over the period of 1-8 months post symptom onset (SO) and explored the determinants of persisting immunoglobulin (Ig) seropositivity. Six hundred sixty-two HCWs were interviewed for anamnestic data and tested for IgG targeting the spike protein (S1 and S2) and IgM targeting the receptor-binding domain. A Cox regression model was used to explore potential predictors of seropositivity with respect to the time lapse between SO and serology testing. 82.9% and 44.7% of HCWs demonstrated IgG and IgM seropositivity, respectively, with a mean interval of 83 days between SARS-CoV-2 detection and serology testing. On average, HCWs reported seven symptoms in the acute phase lasting 20 days. IgG seropositivity rates among HCWs decreased gradually to 80%, 50%, and 35% at 3, 6, and 8 months after SO, while IgM seropositivity fell rapidly to 60%,15%, and 0% over the same time intervals. The number of symptoms was the only predictor of persisting IgG seropositivity (odds ratio [OR] 1.096, 95% confidence interval [CI] 1.003-1.199, p = 0.043) and symptom duration a predictor of IgM seropositivity (OR 1.011, 95% CI 1.004-1.017, p = 0.002). Infection-induced anti-SARS-CoV-2 IgG rates drop to a third in seropositive participants over the course of 8 months. Symptom count and duration in the acute phase of COVID-19 are both relevant to the subsequent kinetics of antibody responses.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30302 - Epidemiology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Medical Virology

ISSN

0146-6615

e-ISSN

1096-9071

Svazek periodika

94

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

8

Strana od-do

3731-3738

Kód UT WoS článku

000784804700001

EID výsledku v databázi Scopus

2-s2.0-85128501889